Early safety check for new sepsis clotting drug
NCT ID NCT07176728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called BAY 3389934 in 16 healthy Japanese adults to see if it is safe and how the body handles it. The drug is being developed to treat a serious blood clotting condition that can happen with severe infections (sepsis). Participants received either the drug or a placebo through an IV, and researchers monitored for side effects and measured drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION (DIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SOUSEIKAI Fukuoka Mirai Hospital
Fukuoka, Fukuoka Pref, 813-0017, Japan
-
SOUSEIKAI Fukuoka Mirai Hospital
Fukuoka, 813-0017, Japan